Differential response malignant human B-cells anti-IgM immunoglobulin anti-mu B-cell growth factor unique direct cytotoxicity anti-mu prolymphocytic leukemia cells vitro thymidine uptake cells prolymphocytic leukemia PLL chronic lymphocytic leukemia CLL plasma cell leukemia PCL patients response culture anti-human IgM antibody anti-mu B-cell growth factor BCGF contrast stimulatory effect normal B-cell cultures divalent anti-mu antibody autonomous proliferation cytotoxicity PLL cell cultures independent complement Fc-receptor-mediated mechanisms stimulation inhibition slgM+ CLL slgM- PCL cells inhibitory effect PLL cells anti-mu concentration stimulatory threshold normal cells Significant impairment trypan blue exclusion hours morphological cellular changes programmed cell death mechanism apoptosis cytotoxicity independent slgM-staining intensity autonomous BCGF-augmented DNA synthetic activity PLL cells similar patients PLL prolymphocytic transformation CLL Cells PLL patient elutriation fractions BCGF-unresponsive large cell fraction marked autonomous DNA synthesis lymphoid cell low uptake BCGF fractions susceptible cytotoxic effect anti-mu data certain slgM-bearing malignant cells susceptible anti-mu-triggered cytotoxicity malignant counterpart tolerogenic normal B-cell subset unique direct cytotoxicity anti-mu therapeutic strategy PLL 